These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23728350)

  • 1. COMS eye plaque brachytherapy dosimetric sensitivity to source photon energy and seed design.
    Gagne NL; Rivard MJ
    Appl Radiat Isot; 2013 Sep; 79():62-6. PubMed ID: 23728350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive dosimetric comparison between (131)Cs and (125)I brachytherapy sources for COMS eye plaque implant.
    Zhang H; Martin D; Chiu-Tsao ST; Meigooni A; Thomadsen BR
    Brachytherapy; 2010; 9(4):362-72. PubMed ID: 20116342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based dose calculations for COMS eye plaque brachytherapy using an anatomically realistic eye phantom.
    Lesperance M; Inglis-Whalen M; Thomson RM
    Med Phys; 2014 Feb; 41(2):021717. PubMed ID: 24506608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
    Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
    Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of material heterogeneity dosimetric effects using radiochromic film for COMS eye plaques loaded with (125)I seeds (model I25.S16).
    Acar H; Chiu-Tsao ST; Ozbay I; Kemikler G; Tuncer S
    Med Phys; 2013 Jan; 40(1):011708. PubMed ID: 23298078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 16 mm OSU-Nag and COMS eye plaques.
    Zhang H; Davidorf F; Qi Y
    J Appl Clin Med Phys; 2012 May; 13(3):3632. PubMed ID: 22584165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function.
    Gagne NL; Leonard KL; Rivard MJ
    Med Phys; 2012 Jun; 39(6):3332-42. PubMed ID: 22755715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monte Carlo simulation of COMS ophthalmic applicators loaded with Bebig I25.S16 seeds and comparison with planning system predictions.
    Miras H; Terrón JA; Lallena AM
    Phys Med; 2013 Nov; 29(6):670-6. PubMed ID: 22858007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques.
    Johnson JE; Deufel CL; Furutani KM
    Brachytherapy; 2016; 15(5):661-8. PubMed ID: 27475484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom.
    Lesperance M; Martinov M; Thomson RM
    Med Phys; 2014 Mar; 41(3):031706. PubMed ID: 24593710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying the dosimetric influences of radiation coverage and brachytherapy implant placement uncertainty on eye plaque size selection.
    Gagne NL; Rivard MJ
    Brachytherapy; 2013; 12(5):508-20. PubMed ID: 23466357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved treatment planning for COMS eye plaques.
    Astrahan MA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1227-42. PubMed ID: 15752905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ROPES eye plaque brachytherapy dosimetry for two models of (103)Pd seeds.
    Saidi P; Sadeghi M; Shirazi A; Tenreiro C
    Australas Phys Eng Sci Med; 2011 Jun; 34(2):223-31. PubMed ID: 21452056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy.
    Thomson RM; Taylor RE; Rogers DW
    Med Phys; 2008 Dec; 35(12):5530-43. PubMed ID: 19175111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using
    Lee YC; Lin SC; Kim Y
    Radiat Oncol; 2018 Nov; 13(1):221. PubMed ID: 30424782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement.
    Morrison H; Larocque MP; Menon G; Sloboda RS; Weis E
    Brachytherapy; 2019; 18(5):668-674. PubMed ID: 31272841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneous dose calculations for Collaborative Ocular Melanoma Study eye plaques using actual seed configurations and Task Group Report 43 formalism.
    Deufel CL; Furutani KM
    Brachytherapy; 2015; 14(2):209-30. PubMed ID: 25533415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of prescription depth, dose rate, plaque size, and source loading on the central axis using 103Pd, 125I, and 131Cs.
    Rivard MJ; Melhus CS; Sioshansi S; Morr J
    Brachytherapy; 2008; 7(4):327-35. PubMed ID: 18782684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monte Carlo-based dosimetry of proposed bi-radionuclide (
    Mishra S; Selvam TP; Sahoo S; Saxena SK; Kumar Y; Sapra BK
    Med Phys; 2024 Oct; 51(10):7561-7573. PubMed ID: 38935327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial evaluation of Advanced Collapsed cone Engine dose calculations in water medium for I-125 seeds and COMS eye plaques.
    Morrison H; Menon G; Larocque MP; van Veelen B; Niatsetski Y; Weis E; Sloboda RS
    Med Phys; 2018 Mar; 45(3):1276-1286. PubMed ID: 29383721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.